Spero Therapeutics Inc (NASDAQ:SPRO)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as low as $10.88. Spero Therapeutics shares last traded at $10.90, with a volume of 1,168 shares traded.

SPRO has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Garrett Motion from a “hold” rating to a “sell” rating in a report on Wednesday, March 20th. Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price target on shares of Spero Therapeutics in a report on Thursday, May 9th. Finally, TheStreet downgraded Tilly’s from a “b-” rating to a “c+” rating in a report on Tuesday, June 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $20.25.

The company has a quick ratio of 17.48, a current ratio of 17.48 and a debt-to-equity ratio of 0.04. The stock has a fifty day moving average price of $11.60. The firm has a market cap of $197.15 million, a PE ratio of -4.02 and a beta of 2.11.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.49. The firm had revenue of $7.72 million during the quarter, compared to the consensus estimate of $1.25 million. Spero Therapeutics had a negative return on equity of 34.34% and a negative net margin of 342.70%. As a group, sell-side analysts expect that Spero Therapeutics Inc will post -3.06 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of SPRO. Marshall Wace LLP acquired a new stake in shares of Spero Therapeutics in the 1st quarter valued at about $39,000. Rhumbline Advisers acquired a new stake in shares of Spero Therapeutics in the 4th quarter valued at about $62,000. PNC Financial Services Group Inc. grew its stake in shares of Spero Therapeutics by 58.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 15,800 shares of the company’s stock valued at $98,000 after buying an additional 5,800 shares during the period. IHT Wealth Management LLC acquired a new stake in shares of Spero Therapeutics in the 4th quarter valued at about $115,000. Finally, Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics in the 1st quarter valued at about $134,000. Institutional investors own 46.70% of the company’s stock.

About Spero Therapeutics (NASDAQ:SPRO)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Featured Article: What is a portfolio manager?

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.